FibroGen (FGEN) Competitors $6.89 -0.03 (-0.43%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$6.85 -0.04 (-0.58%) As of 08/1/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. SKYE, MCRB, CNTB, SAVA, ZURA, COYA, CLYM, SCLX, HLVX, and ANIXShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Skye Bioscience (SKYE), Seres Therapeutics (MCRB), Connect Biopharma (CNTB), Cassava Sciences (SAVA), Zura Bio (ZURA), Coya Therapeutics (COYA), Climb Bio (CLYM), Scilex (SCLX), HilleVax (HLVX), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Its Competitors Skye Bioscience Seres Therapeutics Connect Biopharma Cassava Sciences Zura Bio Coya Therapeutics Climb Bio Scilex HilleVax Anixa Biosciences Skye Bioscience (NASDAQ:SKYE) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation. Does the media refer more to SKYE or FGEN? In the previous week, Skye Bioscience had 3 more articles in the media than FibroGen. MarketBeat recorded 3 mentions for Skye Bioscience and 0 mentions for FibroGen. Skye Bioscience's average media sentiment score of 0.45 beat FibroGen's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media. Company Overall Sentiment Skye Bioscience Neutral FibroGen Neutral Which has stronger valuation & earnings, SKYE or FGEN? Skye Bioscience has higher earnings, but lower revenue than FibroGen. Skye Bioscience is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$26.57M-$0.82-4.16FibroGen$29.62M0.94-$47.58M-$2.50-2.76 Which has more risk & volatility, SKYE or FGEN? Skye Bioscience has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Is SKYE or FGEN more profitable? Skye Bioscience has a net margin of 0.00% compared to FibroGen's net margin of -9.73%. FibroGen's return on equity of 0.00% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -53.92% -48.58% FibroGen -9.73%N/A -24.77% Do analysts prefer SKYE or FGEN? Skye Bioscience presently has a consensus target price of $16.60, indicating a potential upside of 386.80%. FibroGen has a consensus target price of $250.00, indicating a potential upside of 3,528.45%. Given FibroGen's higher possible upside, analysts plainly believe FibroGen is more favorable than Skye Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals believe in SKYE or FGEN? 21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 4.5% of Skye Bioscience shares are owned by insiders. Comparatively, 3.1% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummarySkye Bioscience beats FibroGen on 9 of the 15 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.85M$2.50B$5.52B$9.37BDividend YieldN/A1.80%4.74%4.13%P/E Ratio-2.769.0928.9923.79Price / Sales0.94687.56440.5196.33Price / CashN/A155.1435.0756.59Price / Book-0.144.838.255.54Net Income-$47.58M$31.62M$3.25B$259.97M7 Day Performance-7.52%-5.28%-3.75%-4.67%1 Month Performance21.09%3.12%2.99%3.29%1 Year Performance-35.61%-2.00%25.34%17.92% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen4.406 of 5 stars$6.89-0.4%$250.00+3,528.4%-35.6%$27.85M$29.62M-2.76570Upcoming EarningsSKYESkye Bioscience1.4574 of 5 stars$3.74-4.3%$16.60+343.9%-37.2%$115.87MN/A-4.5611Gap DownMCRBSeres Therapeutics2.9424 of 5 stars$13.24-8.9%$73.67+456.4%-44.0%$115.61MN/A-2.88330News CoverageUpcoming EarningsCNTBConnect Biopharma2.6254 of 5 stars$2.08-6.3%$7.00+236.5%+78.6%$115.57M$26.03M0.00110Short Interest ↑SAVACassava Sciences3.5914 of 5 stars$2.38+1.3%$54.50+2,189.9%-92.7%$114.98MN/A-1.5930ZURAZura Bio3.6284 of 5 stars$1.62-1.2%$14.33+784.8%-58.8%$110.77MN/A-2.313News CoveragePositive NewsCOYACoya Therapeutics1.9462 of 5 stars$6.62-0.7%$16.50+149.2%-3.3%$110.75M$3.55M-6.196CLYMClimb Bio2.5195 of 5 stars$1.60+10.3%$9.00+462.5%N/A$108.13MN/A-0.679Positive NewsHigh Trading VolumeSCLXScilex2.0842 of 5 stars$15.52+29.8%$455.00+2,831.7%-73.4%$107.86M$56.59M-0.5380News CoverageGap DownHigh Trading VolumeHLVXHilleVax1.8408 of 5 stars$2.13-0.9%$2.00-6.1%+20.0%$106.80MN/A-0.9920News CoveragePositive NewsANIXAnixa Biosciences3.4092 of 5 stars$3.29+2.2%$9.00+173.6%-8.8%$105.97M$210K-8.665 Related Companies and Tools Related Companies Skye Bioscience Competitors Seres Therapeutics Competitors Connect Biopharma Competitors Cassava Sciences Competitors Zura Bio Competitors Coya Therapeutics Competitors Climb Bio Competitors Scilex Competitors HilleVax Competitors Anixa Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
